We have shown that CDK4/6 inhibition induces ribosomal biogenesis stress in CCA, leading to acquired vulnerability to ribosomal stressors such as oxaliplatin, phenanthriplatin, and actinomycin [90]. The gene discussed is CDK4; the disease is cholangiocarcinoma.